JP Morgan Chase
ORGO icon

JP Morgan Chase’s Organogenesis Holdings ORGO Stock Holding History

JP Morgan Chase’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.4K Buy
28,692
+703
+3% +$1.72K ﹤0.01% 6278
2026
Q1 		$64.1K Sell
27,989
-39,546
-59% -$137K ﹤0.01% 6075
2025
Q4 		$350K Sell
67,535
-146,797
-68% -$711K ﹤0.01% 5241
2025
Q3 		$904K Sell
214,332
-85,334
-28% -$397K ﹤0.01% 4663
2025
Q2 		$1.1M Sell
299,666
-4,646
-2% -$17.3K ﹤0.01% 4314
2025
Q1 		$1.31M Buy
304,312
+23,315
+8% +$94.1K ﹤0.01% 4162
2024
Q4 		$899K Buy
280,997
+75,054
+36% +$252K ﹤0.01% 4706
2024
Q3 		$589K Buy
205,943
+106,823
+108% +$300K ﹤0.01% 4795
2024
Q2 		$278K Sell
99,120
-67,505
-41% -$181K ﹤0.01% 4979
2024
Q1 		$473K Buy
166,625
+120,161
+259% +$408K ﹤0.01% 4831
2023
Q4 		$190K Sell
46,464
-1,582
-3% -$4.43K ﹤0.01% 5412
2023
Q3 		$153K Sell
48,046
-7,643
-14% -$24.3K ﹤0.01% 5228
2023
Q2 		$185K Sell
55,689
-214
-0.4% -$632 ﹤0.01% 5117
2023
Q1 		$119K Buy
55,903
+15,122
+37% +$37.4K ﹤0.01% 5349
2022
Q4 		$110K Sell
40,781
-24,407
-37% -$71.2K ﹤0.01% 5319
2022
Q3 		$212K Buy
65,188
+3,598
+6% +$16.3K ﹤0.01% 4923
2022
Q2 		$301K Buy
61,590
+10,777
+21% +$66.3K ﹤0.01% 4852
2022
Q1 		$387K Buy
50,813
+19,932
+65% +$154K ﹤0.01% 4856
2021
Q4 		$285K Sell
30,881
-33,352
-52% -$354K ﹤0.01% 5158
2021
Q3 		$915K Sell
64,233
-55,491
-46% -$862K ﹤0.01% 4376
2021
Q2 		$1.99M Buy
119,724
+52,013
+77% +$970K ﹤0.01% 3797
2021
Q1 		$1.23M Buy
67,711
+4,985
+8% +$67.5K ﹤0.01% 4078
2020
Q4 		$472K Buy
62,726
+47,702
+318% +$227K ﹤0.01% 4403
2020
Q3 		$58K Sell
15,024
-3,278
-18% -$12.9K ﹤0.01% 4900
2020
Q2 		$70K Sell
18,302
-1,726
-9% -$6.22K ﹤0.01% 4700
2020
Q1 		$65K Buy
20,028
+5,852
+41% +$25K ﹤0.01% 4654
2019
Q4 		$69K Buy
14,176
+10,722
+310% +$67.9K ﹤0.01% 5020
2019
Q3 		$23K Buy
3,454
+560
+19% +$3.12K ﹤0.01% 5378
2019
Q2 		$22K Buy
2,894
+2,094
+262% +$15.4K ﹤0.01% 5421
2019
Q1 		$6K Buy
+800
New +$16K ﹤0.01% 5603

Other funds holding ORGO

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

JP Morgan Chase's ORGO Position: Q2 2026 in Review

JP Morgan Chase increased its Organogenesis Holdings (ORGO) stake by 2.5% in Q2 2026, buying an estimated $1.72K and bringing the position to 28,692 shares worth $69.4K. The position accounts for ﹤0.01% of the portfolio, ranked #6278.

JP Morgan Chase first reported a position in ORGO in Q1 2019 and has held it in 30 quarters since. The position peaked at $1.99M in Q2 2021. 136 funds tracked by Wall St. Rank hold ORGO as of Q2 2026.

  • JP Morgan Chase held 28,692 shares of Organogenesis Holdings worth $69.4K as of Q2 2026.
  • JP Morgan Chase bought 703 Organogenesis Holdings shares in Q2 2026, an estimated $1.72K.
  • Organogenesis Holdings made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6278 holding.
  • JP Morgan Chase first reported a position in Organogenesis Holdings in Q1 2019 and has held it in 30 quarters since.
  • JP Morgan Chase's Organogenesis Holdings position peaked at $1.99M in Q2 2021.
  • 136 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.